ArticleJournal of translational medicine2025
Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundPancreatic acinar cell carcinoma (ACC) is a rare primary neoplasm of acinar cell origin. Histologically, it can present as pure ACC or mixed with neuroendocrine or ductal differentiation. We studied whether ACC shared genomic similarities with pancreatic ductal adenocarcinoma (PDAC) or well-differentiated pancreatic neuroendocrine tumors (PNET) using the hidden genome classifier methodology.
methodsThe hidden genome classifier was trained using next-generation sequencing of KRAS wild-type (KRAS-WT) PDAC (n = 251), KRAS-mutated (KRAS-mut) PDAC (n = 1872) and PNET (n = 127). We applied the classifier to 62 primary and metastatic ACC samples from two institutions to identify the genomic class and its relationship to histologic differentiation and clinical outcomes.
resultsAccording to the classifier, KRAS mutations and tumor mutation burden contributed to the KRAS-mut PDAC class, while ATRX, VHL and SETD2 mutations contributed to the PNET class. Copy number alterations (CNA) in chromosomes 1q and 11q were key factors in the genomic classification of KRAS-WT PDAC. Most ACC (49/62) aligned genomically with KRAS-WT PDAC. Fifteen ACCs had mixed histology, and the majority of those (11/15) also classified as KRAS-WT PDAC. CNA were present in most ACC tumors, even those without mutations in DNA damage repair or chromatin modification pathways. The predicted genomic class was not associated with survival outcomes.
conclusionsThe hidden genome classifier found most ACC shares genomic similarities with KRAS-WT PDAC, independent of ductal or neuroendocrine differentiation. This may reflect a common cell of origin in ACC tumorigenesis and explain the improved clinical outcome compared to KRAS-mut PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.